Natixis Bleichroeder Upgrades Thoratec (THOR) to Buy
More News related to THOR
- Thoratec Presentation at Piper Jaffray Conference to be Webcast
- Auriga Reiterates a 'Buy' Rating on Thoratec Corp. (THOR); Strong Pivotal Data Should Lead to DT Approval
- Thoratec Lab (THOR) volatility decreases as shares rally 10% on positive trial data
- Thoratec (THOR) Releases Data for HeartMate II Pivotal Trial
- Destination Therapy Trial Data Demonstrate Superiority for HeartMate II(R) Over HeartMate(R) XVE
Natixis Bleichroeder upgrades Thoratec (Nasdaq: THOR) from Hold to Buy. Price target from $24 to $33.
To see more analyst ratings on THOR Click Here.
Thoratec Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of proprietary medical devices used for circulatory support.
Related Categories
UpgradesStocks Mentioned
-0.42Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
